Name: 글로벌 시장 동향
SKU: PH51
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 전신성 루푸스(SLE) 시장은 2022년 18억 9,320만 달러에 달했으며, 2030년까지 32억 9,570만 달러로 성장할 것으로 예상됩니다. SLE 시장은 예측 기간(2023~2030년) 동안 연평균 7.3%의 성장률을 보일 것으로 전망됩니다.
전신성 루푸스(SLE)는 면역 체계가 건강한 조직을 잘못 공격하여 피부, 관절, 신장, 심장, 폐, 뇌 등을 손상시키는 만성 자가면역 질환입니다. SLE는 여성에게 더 흔하며, 일반적으로 25세에서 45세 사이에 발생합니다.
만성 염증과 다양한 증상이 나타나 삶의 질을 저하시킬 수 있습니다. 전 세계 전신성 루푸스 시장은 질환에 대한 이해도 증가, 진단율 향상, 그리고 새로운 치료법 개발로 인해 향후 몇 년 동안 크게 성장할 것으로 예측됩니다.

시장 동향
정부 차원의 다양한 정책 추진이 전 세계 전신성 루푸스 시장 성장을 견인할 것으로 예상됩니다.

전 세계 정부는 전신성 루푸스 치료 및 요법에 대한 접근성을 높이고, 연구 개발에 대한 재정 지원을 확대하며, 환자 예후를 개선하는 규제를 장려하기 위해 노력하고 있습니다.
예를 들어, 미국 질병통제예방센터(CDC)의 2022년 보고서에 따르면, CDC-RFA-DP20-2008은 5년 협력 계약이 체결된 자금 지원 공고(NOFO)입니다. 이 협력 계약의 주요 목표는 루푸스에 대한 인식과 역량을 향상시키기 위한 국가적 정책을 추진하는 국가 기관을 지원하고, 관련 협력을 구축하는 것입니다.

이 협약의 목표는 루푸스 징후를 인지하고 발견 시 적절한 조치를 취할 수 있는 의료 전문가의 수를 늘리는 것입니다. 또한, 이 협약은 루푸스 환자의 자가 관리 도구 및 서비스 참여를 확대하여 자가 관리 행동에 긍정적인 변화를 가져오는 것을 목표로 합니다. 따라서 위에서 언급한 요인들이 예측 기간 동안 전 세계 전신성 루푸스 시장의 성장을 견인할 것으로 예상됩니다.
전 세계 전신성 루푸스 시장은 치료의 부작용으로 인해 제약을 받을 수 있습니다.
기존의 많은 전신성 루푸스 치료법은 잠재적으로 심각한 부작용을 가지고 있어 환자들이 사용을 꺼릴 수 있습니다. 환자들은 상당한 부작용이 있는 치료법을 꺼릴 수 있으며, 이는 시장 성장을 제한하는 큰 요인이 될 수 있습니다.
프레드니손은 염증을 줄이고 관절통, 피부 발진과 같은 증상을 완화하는 데 도움이 되는 코르티코스테로이드의 한 예이지만, 체중 증가, 고혈압, 골다공증과 같은 심각한 부작용을 일으킬 수도 있습니다.

COVID-19 영향 분석
COVID-19 팬데믹 이후, 전신성 루푸스(SLE)는 세계 시장에 상당한 영향을 미쳤습니다. 환자의 의료 접근성 제한은 팬데믹의 주요 영향 중 하나입니다. SLE 환자 중 상당수는 면역 체계가 약화되어 COVID-19에 감염될 경우 중증으로 발전할 가능성이 높기 때문에 의료기관을 찾는 사람이 줄어들면서 진단 및 치료가 지연됩니다.
이는 환자의 예후에 악영향을 미칠 수 있습니다. 또한 COVID-19 팬데믹은 SLE 치료제의 시장 공급을 저해하여 환자와 의료 시스템 모두에게 부족 현상과 가격 상승을 초래했습니다.
러시아-우크라이나 분쟁 분석
러시아와 우크라이나 간의 갈등은 전 세계 전신성 루푸스(SLE) 시장, 특히 SLE 치료제 공급망에 예상치 못한 결과를 초래할 수 있습니다. 우크라이나는 다른 국가에 의약품을 수출하는 주요 제약 생산국으로 성장하고 있습니다. 전쟁으로 인해 생산 시설이나 운송 경로가 파괴되거나 폐쇄될 경우, SLE 치료제 공급망에 차질이 생길 수 있습니다.
또한, 분쟁으로 인해 해당 지역의 의료 인프라와 접근성이 저하될 수 있으며, 이로 인해 우크라이나와 주변 지역의 SLE 환자들이 진단과 치료를 더 오래 기다려야 할 수도 있습니다. 그러나 전 세계 SLE 치료제 시장은 다양하며, 특정 지역이나 국가에 크게 의존하지 않습니다.
세분화 분석
전 세계 전신성 루푸스(SLE) 시장은 약물 종류, 투여 방식, 유통 채널 및 지역별로 세분화됩니다.
병원 약국 부문이 전 세계 전신성 루푸스 시장을 주도할 것으로 예상됩니다.
전 세계 전신성 루푸스(SLE) 치료제 유통은 병원 약국이 주도하며, 시장 점유율은 42.4%에 달할 것으로 예상됩니다. 병원 약국은 환자에게 필수 의약품 및 기타 치료제를 제공하며, 특히 중증 또는 복합적인 형태의 전신성 홍반성 루푸스(SLE) 환자에게 주요 치료 거점 역할을 합니다. 개인 맞춤형 약물 용량 및 모니터링, 정맥 주입이나 진단 검사와 같은 전문 치료법 이용은 병원 약사가 제공하는 이점입니다.
또한, 병원 약사는 이미 의료 전문가와 긴밀한 관계를 유지하고 있어 약물 처방 및 모니터링, 치료 관련 소통 및 조율이 더욱 용이합니다. 따라서 이러한 요인들로 인해 병원 약국 부문은 전 세계 SLE 시장 성장을 가속화하는 데 중요한 역할을 할 것으로 예상됩니다.
지역 분석
북미 지역이 전 세계 SLE 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
전 세계 SLE 시장에서 북미 지역이 3분의 1의 시장 점유율을 차지하며 지배적인 위치를 차지하고 있는데, 이는 여러 요인 중 하나로, 북미 지역에서 SLE에 대한 지식이 풍부하여 질환 및 이용 가능한 치료법에 대한 이해도가 높기 때문입니다. 둘째, 다른 지역에 비해 북미는 의료 시스템이 더 잘 발달되어 있어 SLE 환자들이 의료 서비스와 전문 치료에 더 쉽게 접근할 수 있습니다.
또한 북미의 바이오 제약 회사에 투자하는 재단과 독립 벤처 기업이 더 많아 새로운 SLE 치료제 개발에 도움이 되었습니다. 예를 들어, 2023년 3월 애브비는 중등도에서 고도 활동성 전신성 루푸스(SLE) 환자를 대상으로 우파다시티닙(RINVOQ, 30mg)을 단독 투여하거나 브루톤 티로신 키나제 억제제(엘수브루티닙, 60mg)와 병용 투여(ABBV-599)하는 2상 임상 연구 결과를 발표했습니다.

경쟁 환경
시장의 주요 글로벌 업체로는 Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, Merck KGaA 등이 있습니다.
보고서 구매 이유

• 약물 종류, 투여 방식, 유통 채널, 지역별 글로벌 전신성 루푸스 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 글로벌 전신성 루푸스 시장의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

전 세계 전신성 루푸스 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).
Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.
Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.
Market Dynamics
The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.
Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.
For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.
The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.
The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.
Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.
Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.
COVID-19 Impact Analysis
In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.
This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems..
Russia Ukraine Conflict Analysis
The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.
In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.
Segment Analysis
The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.
The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.
The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.
Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.
Geographical Analysis
North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.
The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.
In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.
Competitive Landscape
The major global players in the market include Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.
Why Purchase the Report?
• To visualize the global systemic lupus erythematosus- market segmentation based on drug class, mode of delivery, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global systemic lupus erythematosus market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Mode of Delivery
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rising number of government initiatives is expected to drive the global systemic lupus erythematosus market.
4.1.2. Restraints
4.1.2.1. The global systemic lupus erythematosus market may face constraints due to adverse effects of treatment.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Antimalarial Drugs
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Steroidal Anti-Inflammatory Drugs
7.4. Cytotoxic And Immunosuppressive Drugs
7.5. Biologics
7.6. Others
8. By Mode of Delivery
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
8.1.2. Market Attractiveness Index, By Mode of Delivery
8.2. Intravenous
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Oral
8.5. Topical
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Retail Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospital Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Anthera Pharmaceuticals Inc. *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Eli Lilly
12.3. GlaxoSmithKline Plc
12.4. F. Hoffmann-La Roche Ltd
12.5. Pfizer Limited
12.6. Sanofi
12.7. Lycera Corporation
12.8. Bristol-Myers Squibb
12.9. ImmuPharma Plc
12.10. Merck KGaA
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Anthera Pharmaceuticals Inc., 4.	Key Developments, Eli Lilly, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, Merck KGaA

표 목록 (Tables)

List of Tables

Table 1 Global Systemic Lupus Erythematosus Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Systemic Lupus Erythematosus Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Systemic Lupus Erythematosus Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 7 Global Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 9 Global Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Systemic Lupus Erythematosus Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Systemic Lupus Erythematosus Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 14 North America Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 15 North America Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Systemic Lupus Erythematosus Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 18 South America Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 19 South America Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Systemic Lupus Erythematosus Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 22 Europe Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 23 Europe Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Systemic Lupus Erythematosus Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Systemic Lupus Erythematosus Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Systemic Lupus Erythematosus Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Systemic Lupus Erythematosus Market Value, By Mode of Delivery, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Systemic Lupus Erythematosus Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Anthera Pharmaceuticals Inc.: Overview

Table 33 Anthera Pharmaceuticals Inc.: Product Portfolio

Table 34 Anthera Pharmaceuticals Inc.: Key Developments

Table 35 Eli Lilly: Overview

Table 36 Eli Lilly: Product Portfolio

Table 37 Eli Lilly: Key Developments

Table 38 GlaxoSmithKline Plc: Overview

Table 39 GlaxoSmithKline Plc: Product Portfolio

Table 40 GlaxoSmithKline Plc: Key Developments

Table 41 F. Hoffmann-La Roche Ltd: Overview

Table 42 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 43 F. Hoffmann-La Roche Ltd: Key Developments

Table 44 Pfizer Limited: Overview

Table 45 Pfizer Limited: Product Portfolio

Table 46 Pfizer Limited: Key Developments

Table 47 Sanofi: Overview

Table 48 Sanofi: Product Portfolio

Table 49 Sanofi: Key Developments

Table 50 Lycera Corporation: Overview

Table 51 Lycera Corporation: Product Portfolio

Table 52 Lycera Corporation: Key Developments

Table 53 Bristol-Myers Squibb: Overview

Table 54 Bristol-Myers Squibb: Product Portfolio

Table 55 Bristol-Myers Squibb: Key Developments

Table 56 ImmuPharma Plc: Overview

Table 57 ImmuPharma Plc: Product Portfolio

Table 58 ImmuPharma Plc: Key Developments

Table 59 Merck KGaA: Overview

Table 60 Merck KGaA: Product Portfolio

Table 61 Merck KGaA: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 2 Global Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 3 Global Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 4 Global Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Systemic Lupus Erythematosus Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Systemic Lupus Erythematosus Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Antimalarial Drugs Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 8 Non-Steroidal Anti-Inflammatory Drugs Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 9 Cytotoxic and Immunosuppressive Drugs Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 10 Biologics Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 11 Others Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 12 Global Systemic Lupus Erythematosus Market Y-o-Y Growth, By Mode of Delivery, 2022-2030 (%)

Figure 13 Intravenous Mode of Delivery in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 14 Subcutaneous Mode of Delivery in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 15 Oral Mode of Delivery in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 16 Topical Mode of Delivery in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 17 Global Systemic Lupus Erythematosus Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 18 Retail Pharmacies Distribution Channel in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 19 Hospitals Distribution Channel in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 20 Online Pharmacies Distribution Channel in Global Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 21 Global Systemic Lupus Erythematosus Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 23 Asia-Pacific Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 24 Europe Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 25 South America Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 26 Middle East and Africa Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 27 North America Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 28 North America Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 29 North America Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 30 North America Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 31 North America Systemic Lupus Erythematosus Market Share, By Country, 2023 & 2031 (%)

Figure 32 South America Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 33 South America Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 34 South America Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 35 South America Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 36 South America Systemic Lupus Erythematosus Market Share, By Country, 2023 & 2031 (%)

Figure 37 Europe Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 39 Europe Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 40 Europe Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 41 Europe Systemic Lupus Erythematosus Market Share, By Country, 2023 & 2031 (%)

Figure 42 Asia-Pacific Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 43 Asia-Pacific Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 44 Asia-Pacific Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 45 Asia-Pacific Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 46 Asia-Pacific Systemic Lupus Erythematosus Market Share, By Country, 2023 & 2031 (%)

Figure 47 Middle East & Africa Systemic Lupus Erythematosus Market Value, 2022-2031 (US$ Million)

Figure 48 Middle East & Africa Systemic Lupus Erythematosus Market Share, By Drug Class, 2023 & 2031 (%)

Figure 49 Middle East & Africa Systemic Lupus Erythematosus Market Share, By Mode of Delivery, 2023 & 2031 (%)

Figure 50 Middle East & Africa Systemic Lupus Erythematosus Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 51 Anthera Pharmaceuticals Inc.: Financials

Figure 52 Eli Lilly: Financials

Figure 53 GlaxoSmithKline Plc: Financials

Figure 54 F. Hoffmann-La Roche Ltd: Financials

Figure 55 Pfizer Limited: Financials

Figure 56 Sanofi: Financials

Figure 57 Lycera Corporation: Financials

Figure 58 Bristol-Myers Squibb: Financials

Figure 59 ImmuPharma Plc: Financials

Figure 60 Merck KGaA: Financials

세계 전신성 루푸스 시장 – 2023-2030

Global Systemic Lupus Erythematosus Market - 2023-2030